Stopped: NIA funded the first phase of the R21. The clinical trial never began as the R33 was not supported.
Polypharmacy is common among older adults in the United States and is associated with harms such as adverse drug reactions and higher costs of care. This pilot-phase project is designed to test two electronic health record (EHR)-based behavioral economic nudges to help primary care clinicians reduce the rate of high-risk polypharmacy among their older adult patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
High-risk polypharmacy criterion: Fall condition-drug interaction
Timeframe: 28 months
High-risk polypharmacy criterion: Fall drug-drug interaction
Timeframe: 28 month
High-risk polypharmacy criterion: CKD-glyburide/glimepiride interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CKD-NSAID interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CHF-NSAID interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CHF-non-dihydropyridine calcium channel blocker interaction
Timeframe: 28 months
High-risk polypharmacy criterion: CHF-thiazolidinedione interaction
Timeframe: 28 months